Spectrum of activity:
|
Gram-negative
|
Details of activity:
|
Active against Mycobacterium leprae, Acinetobacter baumannii, Salmonella Typhimurium, Streptococcus penumoniae, Staphylococcus aureus, and Neisseria gonorrhoeae; targets DNA gyrase
|
Description:
|
Synthetic compound; shows similar pharmacophore to WQ-3034 with 3-isopropylaminoazetizine-1-yl at the R7 position and methyl group at the R8 position
|
Institute where first reported:
|
Wakunaga Pharmaceutical Co., Ltd. (Osaka, Japan); Division of Bioresources, Hokkaido University Research Center for Zoonosis Control; The Global Station for Zoonosis Control, Hokkaido University Global Institution for Collaborative Research and Education, Sapporo, Japan
|
Year first mentioned:
|
2014
|
Highest developmental phase:
|
Phase 1
|
Development status:
|
Discontinued
|
Reason Dropped:
|
Undisclosed reasons (Kalidex Pharmaceuticals [Menlo Park, CA, USA] who licensed the compound for global development and commercialization rights had ceased operations in 2016)
|